Breaking News Instant updates and real-time market news.

UNH

UnitedHealth

$233.50

13.18 (5.98%)

, ANTM

Anthem

$244.77

10.04 (4.28%)

09:55
10/15/19
10/15
09:55
10/15/19
09:55

Early notable gainers among liquid option names on October 15th

Notable gainers among liquid option names this morning include UnitedHealth (UNH) $232.98 +12.47, Anthem (ANTM) $246.11 +11.37, Cigna (CI) $158.58 +6.99, Charles Schwab (SCHW) $39.18 +1.44, and NVIDIA (NVDA) $192.89 +6.35.

UNH

UnitedHealth

$233.50

13.18 (5.98%)

ANTM

Anthem

$244.77

10.04 (4.28%)

CI

Cigna

$157.49

5.875 (3.87%)

SCHW

Charles Schwab

$38.63

0.89 (2.36%)

NVDA

Nvidia

$192.32

5.81 (3.12%)

  • 15

    Oct

  • 18

    Oct

  • 23

    Oct

  • 27

    Oct

  • 31

    Oct

  • 20

    Nov

UNH UnitedHealth
$233.50

13.18 (5.98%)

10/10/19
RHCO
10/10/19
NO CHANGE
Target $330
RHCO
Hold
SunTrust 'bullish' across healthcare services space ahead of Q3 results
SunTrust analyst David MacDonald says he remains "bullish" across much of the healthcare services space ahead of third quarter results, citing "solid" core trends, "attractive" secular tailwinds, "robust" M&A and "strong" free cash flow. While he expects ongoing intermittent "chop" as industry noise continues to weigh, he views the risk of meaningful structural change as quite low, continues to favor scaled, integrated providers in the ongoing shift towards value and views valuation risk/rewards as increasingly attractive. The analyst tells investors in a research note that he does not necessarily view Q3 results as a meaningful trigger and thinks improved visibility around the election and Democratic primary is key, MacDonald remains bullish on core fundamentals, sees significant inherent sector drivers and says Managed Care remains a favorite fundamental sector. The analyst raised his price target for Anthem (ANTM) to $330 from $290, on Centene (CNC) to $80 from $72, on Cigna (CI) to $260 from $230, on Humana (HUM) to $340 from $310, on Molina (MOH) to $180 from $165, on UnitedHealth (UNH) to $330 from $310, on WellCare (WCG) to $340 from $320, on Ensign Group (ENSG) to $60 from $44 and Tivity Health (TVTY) to $24 from $21.
10/10/19
JEFF
10/10/19
DOWNGRADE
Target $235
JEFF
Hold
Jefferies downgrades UnitedHealth to Hold, cuts Managed Care price targets
Jefferies analyst David Windley downgraded UnitedHealth (UNH) to Hold from Buy with a price target of $235, down from $300. Managed Care sentiment "turned abruptly negative a year ago and has stubbornly remained there," Windley tells investors in a research note. Further, the political risk causing this won't likely abate for at least another nine months, contends the analyst. In addition to the political overhang, he's concerned UnitedHealth's (UNH) commercial enrollment is at risk to Anthem (ANTM). Along with the downgrade of UnitedHealth, Windley cut his price target for Buy-rated Anthem to $299 from $365, for Buy-rated Centene (CNC) to $53 from $76, for Buy-rated Cigna (CI) to $203 from $233, for Buy-rated Humana (HUM) to $322 from $352, for Buy-rated Molina Healthcare (MOH) to $133 from $173 and for Hold-rated WellCare (WCG) to $264 from $302.
10/10/19
JEFF
10/10/19
DOWNGRADE
Target $235
JEFF
Hold
UnitedHealth downgraded to Hold from Buy at Jefferies
Jefferies analyst David Windley downgraded UnitedHealth to Hold from Buy with a price target of $235, down from $300.
10/08/19
CANT
10/08/19
NO CHANGE
Target $310
CANT
Overweight
UnitedHealth pullback on policy noise an opportunity, says Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper says shares of UnitedHealth are attractive at current levels. He reiterates an Overweight rating on the name with a $310 price target ahead of the company's Q3 results on October 15. Optum will continue to be a strong growth driver for UnitedHealth, driven by solid performance across all three of the unit's operating segments, Halper tells investors in a pre-earnings research note. The analyst continue believe sweeping changes to the U.S. healthcare system, which has pressured the stock, are unlikely. Policy noise has created an attractive buying opportunity into UnitedHealth, says Halper.
ANTM Anthem
$244.77

10.04 (4.28%)

10/01/19
SPHN
10/01/19
NO CHANGE
SPHN
Stephens lowers price targets for MCOs on 2020 election uncertainty
Stephens analyst Scott Fidel said the uncertainty over the 2020 elections has been a consistent overhang for Managed Care Organization stocks, but the group has underperformed the S&P 500 Index by about 15% since Elizabeth Warren's polling numbers for the Democratic presidential nomination rose above the 18% range in mid-August. Given the continuing uncertainty about the 2020 election, especially in light of Warren's rise and "the Ukraine imbroglio" adding new risks for both Trump and Biden, Fidel lowered his price targets across the MCO group. However, he maintains his ratings, noting that the group now trades at its largest discount to the S&P since February 2010. Fidel lowered his price target price on Anthem (ANTM) shares to $306 from $350, trimmed his Cigna (CI) target to $206 from $225, lowered his Centene (CNC) target to $60 from $72, cut his Humana (HUM) target to $307 from $335, lowered Magellan Health's (MGLN) target to $65 from $74, decreased his Molina Healthcare (MOH) target to $126 from $150, lowered UnitedHealth's (UNH) target to $258 from $290 and cut his target for WellCare (WCG) to $287 from $317.
09/18/19
PIPR
09/18/19
NO CHANGE
PIPR
Managed Care selloff brings buying opportunity, says Piper Jaffray
Piper Jaffray analyst Sarah James believes the recent selloff in shares of Managed Care companies, which she attributes to political concerns, has brought buying opportunities. Now is a good time to start doing work on the names, says James, who sees "initial signs of value funds coming in." Faster moving money will come back into the sector once we get past the fall/winter catalysts, the analyst tells investors in a research note. This gives investors a small window when the sector is out of favor to pick up top performing names, contends James. Her top picks are Anthem (ANTM), Cigna (CI), Humana (HUM), Centene (CNC), Molina Healthcare (MOH) and UnitedHealth (UNH).
CI Cigna
$157.49

5.875 (3.87%)

09/30/19
09/30/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. TSMC (TSM) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Bruce Lu saying after a re-examination of industry capacity builds and order revisions, he thinks he's underestimating the positive impacts on TSMC arising from trade uncertainty. 2. Wells Fargo (WFC) upgraded to Buy from Hold at Argus with analyst Stephen Biggar citing the company's appointment of Charlie Scharf as its new CEO. 3. Cigna (CI) upgraded to Outperform from Market Perform at BMO Capital with analyst Matthew Borsch claiming that the current 8-times his expected forward earnings valuation multiple is "attractive" as the stock represents a "better hedge" against political and health policy uncertainty. 4. Bed Bath & Beyond (BBBY) upgraded to Outperform from Neutral at Wedbush with analyst Seth Basham saying turning around declining retailers is a very difficult task, particularly amidst unfavorable secular trends and soft industry sales growth, but Bed Bath & Beyond has a "good chance of stabilization" in earnings over the next two years as its changes take hold. 5. Restaurant Brands (QSR) upgraded to Neutral from Underperform at Longbow with analyst Alton Stump saying after calls with U.S. Burger King franchisees, he believes same-store sales for Restaurant Brands' Burger King concept were up 4.5%-5.0% in Q3 ahead of his prior estimate of 2.0% growth and consensus at up 3.4%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SCHW Charles Schwab
$38.63

0.89 (2.36%)

10/14/19
SBSH
10/14/19
NO CHANGE
SBSH
Citi opens '30-Day Negative Catalyst Watch' on Waddell & Reed
Citi analyst William Katz opened a "30-Day Negative Catalyst Watch" for Sell-rated Waddell & Reed (WDR) and initiated a "90-Day Positive Catalyst Watch" on Buy-rated Carlyle Group (CG). He also initiated a "Persistent Existentialism" pair trade, or overweight Charles Schwab (SCHW) and underweight TD Ameritrade (AMTD), a stock he downgraded this morning to Sell from Neutral. Into the Q3 earnings season, the analyst lowered his 12-month price targets for the Brokers and Asset Managers to reflect a combination of lower target multiples and reduced earnings prospects.
10/03/19
10/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Market Perform from Outperform at JMP Securities with analyst Joseph Osha saying that while the figures were not "significantly far off" from consensus, delivery unit growth was in low-single-digits with no indications of operational issues. 2. Charles Schwab (SCHW) and E-Trade (ETFC) downgraded to Market Perform from Outperform at Wells Fargo while TD Ameritrade (AMTD) was downgraded to Underperform from Outperform. 3. Teligent (TLGT) downgraded to Market Perform from Outperform at Raymond James with analyst Elliot Wilbur citing the announcement of a strategic review of assets that are non-core to the company's long-term strategy. 4. Insulet (PODD) downgraded to Neutral from Buy at Guggenheim with analyst Chris Pasquale saying while he continues to see the company being competitively well positioned, he now sees the risk/reward as less attractive. 5. Delta Air Lines (DAL) downgraded to Neutral from Buy at Buckingham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/09/19
DBAB
10/09/19
NO CHANGE
DBAB
Hold
Deutsche sees 'major' M&A as potential path for E-Trade, Ameritrade
Charles Schwab's (SCHW) move to cut trade commissions to zero is likely to spur business model changes at TD Ameritrade (AMTD) and E-Trade Financial (ETFC), Deutsche Bank analyst Brian Bedell tells investors in a research note. Instead of managing "persistent" revenue declines, management teams should seek to leverage their strong operating platforms and loyal customer base into a more diversified retail financial service offering that includes online banking, digital wealth management and investment advisory, argues the analyst. This may require "major" M&A for E-Trade and Ameritrade, while Schwab can likely augment its wider range of offerings organically or via smaller bolt on deals, says Bedell. He still views Ameritrade as the "most efficient acquirer" of E-Trade, but finds it no longer clear that the combination "would create a broad enough financial services offering for the new revenue paradigm." One alternative idea could be an E-Trade combination with a digital banking and wealth management platform, says the analyst, who analyzed a potential merger with Goldman Sachs (GS). Bedell also wonders if Ameritrade will eventually explore strategic alternatives or if 43% owner TD Bank (TD) will eventually seek to acquire a much larger controlling stake in the company.
10/09/19
JEFF
10/09/19
NO CHANGE
Target $43
JEFF
Buy
Jefferies says Schwab best positioned discount broker after commission cuts
Jefferies analyst Daniel Fannon said following last week's commission cut announcements that he views Charles Schwab (SCHW) as the best positioned discount broker to capitalize on trends in the industry toward fee-based advice and advisors going independent. Interest rates will "push around near-term profitability," but he believes Schwab's net new asset growth is poised to remain industry-leading, Fannon said. Among publicly traded companies in the space, Fannon still views E-Trade (ETFC) as the most likely M&A candidate, he added. Given the recent commission cuts, he lowered his price target on Schwab shares to $43 from $49, lowered his price target on E-Trade to $44 from $54 and cut his price target on TD Ameritrade (AMTD) to $36 from $55. Fannon has Buy ratings on the first two stocks mentioned and a Hold rating on TD Ameritrade.
NVDA Nvidia
$192.32

5.81 (3.12%)

10/15/19
BOFA
10/15/19
NO CHANGE
Target $250
BOFA
Buy
Nvidia price target raised to $250 from $225 at BofA/Merrill
BofA Merrill Lynch analyst Vivek Arya raised his price target on Nvidia shares to $250 from $225 as he believes the company's data center growth will soon benefit from "the next-big AI landmark," namely natural language processing, or "conversational AI." The ability to accurately listen, understand, speak and contextualize human speech needs compute requirements 100 times that of today's dominant image/video classifier AI machines, said Arya, who sees Nvidia being "in prime position" to benefit from this shift given its portfolio of hardware and software and its developer ecosystem. Arya keeps a Buy rating on Nvidia, which he continues to identify as his top large-cap pick.
10/09/19
PIPR
10/09/19
NO CHANGE
Target $200
PIPR
Overweight
Nvidia's two biggest growth drivers are back, says Piper Jaffray
Piper Jaffray analyst Harsh Kumar believes Nvidia's (NVDA) two biggest growth drivers, namely gaming and data center, are back. Following a round of channel checks, the analyst says Nvidia is one of the best positioned semiconductor companies from a "company-specific catalyst perspective." Gaming, which represents around half of the company's revenue, appears to have settled following the GPU inventory correction, and the segment is setup for a seasonally strong second half of 2019, Kumar tells investors in a research note. In addition, the analyst is convinced Nvidia's data center business appears to have stabilized, and he sees growth in the segment moving forward. Further, Kumar thinks the Mellanox (MLNX) acquisition is on track to close by the end of calendar 2019. Lastly, based on Piper's teen survey results, the analyst believes video game interest remains high among U.S. teens. He keeps an Overweight rating on Nvidia with a $200 price target. The stock closed Tuesday down $7.10 to $177.23.
10/07/19
EVER
10/07/19
NO CHANGE
Target $225
EVER
Outperform
Nvidia price target raised to $225 from $185 at Evercore ISI
Evercore ISI analyst C.J. Muse said in a note before the open that he thinks it is understandable that investors have taken a cautious view on the future growth of Nvidia's Gaming franchise, though he sees a potential recovery coming in the second half and momentum continuing into 2020 and beyond in that part of the company's business. Muse sees at least a 15% compound annual growth rate for Gaming into 2022, led by Notebook Gaming growth, even without giving credit for any contributions from Cloud gaming via wins at CSPs and GeForce Alliance, which could be a source of added upside. The analyst, who now predicts Nvidia EPS approaching $9.25 in the 2021 timeframe, reiterated his Outperform rating on the shares and raised his price target to $225 from $185. Nvidia, which also saw its price target raised to $217 from $190 at RBC Capital this morning, is up 3% to $187.44 in early trading.
10/07/19
RBCM
10/07/19
NO CHANGE
Target $217
RBCM
Outperform
Nvidia price target raised to $217 from $190 at RBC Capital
RBC Capital analyst Mitch Steves raised his price target on Nvidia to $217 and kept his Outperform rating, saying he expects the stock to be the best performing large-cap name in his coverage universe within the next 6-9 months. The analyst cites indications of a pick-up in the gaming demand, which he sees as tracking ahead of the company's plans. Steves also believes that Nvidia's Data Center should recover in Q4 thanks to the product refresh announcement expected in the quarter, further supporting his forecast of expanding gross margins.

TODAY'S FREE FLY STORIES

03:15
11/18/19
11/18
03:15
11/18/19
03:15
General news
FX Update: Sterling has rallied on weekend polls »

FX Update: Sterling has…

01:50
11/18/19
11/18
01:50
11/18/19
01:50
General news
Asian Market Update: »

Asian Market Update:…

HPQ

HP Inc.

$20.17

0.05 (0.25%)

, XRX

Xerox

$38.95

0.295 (0.76%)

20:56
11/17/19
11/17
20:56
11/17/19
20:56
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

HPQ

HP Inc.

$20.17

0.05 (0.25%)

XRX

Xerox

$38.95

0.295 (0.76%)

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

PCG

PG&E

$7.41

0.71 (10.60%)

FOX

Fox Corp.

$33.60

0.14 (0.42%)

FOXA

Fox Corp.

$34.26

0.04 (0.12%)

SNE

Sony

$62.03

0.23 (0.37%)

BR

Broadridge

$119.80

0.485 (0.41%)

MDT

Medtronic

$112.11

2.9 (2.66%)

DIS

Disney

$144.63

-2.56 (-1.74%)

BRK.A

Berkshire Hathaway

$329,361.11

266.11 (0.08%)

BRK.B

Berkshire Hathaway

$219.74

0.38 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 09

    Dec

  • 07

    Jan

RCEL

Avita Medical

$8.13

-0.06 (-0.73%)

20:39
11/17/19
11/17
20:39
11/17/19
20:39
Hot Stocks
Avita Medical appoints David McIntyre CFO »

AVITA Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

20:37
11/17/19
11/17
20:37
11/17/19
20:37
Recommendations
Eidos Therapeutics analyst commentary at Piper Jaffray »

Piper Jaffray sees Eidos…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

COO

Cooper Companies

$301.97

2.64 (0.88%)

20:30
11/17/19
11/17
20:30
11/17/19
20:30
Recommendations
Cooper Companies analyst commentary at Piper Jaffray »

Piper Jaffray reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CRM

Salesforce

$163.20

0.18 (0.11%)

20:21
11/17/19
11/17
20:21
11/17/19
20:21
Recommendations
Salesforce analyst commentary at Jefferies »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 16

    Dec

CCMP

Cabot Microelectronics

$155.89

2.68 (1.75%)

20:15
11/17/19
11/17
20:15
11/17/19
20:15
Earnings
Breaking Earnings news story on Cabot Microelectronics »

Cabot Microelectronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

CCMP

Cabot Microelectronics

$155.89

2.68 (1.75%)

20:15
11/17/19
11/17
20:15
11/17/19
20:15
Earnings
Cabot Microelectronics sees Q1 total revenue approximately flat »

For Q1, the company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

CCMP

Cabot Microelectronics

$155.89

2.68 (1.75%)

20:14
11/17/19
11/17
20:14
11/17/19
20:14
Earnings
Cabot Microelectronics reports Q4 EPS $1.68, consensus $1.63 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

JEF

Jefferies Financial Group

$19.08

0.16 (0.85%)

20:13
11/17/19
11/17
20:13
11/17/19
20:13
Hot Stocks
Jefferies Financial Group to sell 31% interest in National Beef to Marfrig »

Jefferies Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NIO

NIO Inc.

$1.82

0.07 (4.01%)

20:11
11/17/19
11/17
20:11
11/17/19
20:11
Hot Stocks
NIO Inc. appoints Wei Feng CFO »

NIO Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

20:09
11/17/19
11/17
20:09
11/17/19
20:09
Hot Stocks
Barrick Gold to sell 50% stake in Australian mine for $750M in cash »

Barrick Gold Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

15:40
11/17/19
11/17
15:40
11/17/19
15:40
Periodicals
Saracen close to buying Barrick Gold mine stake for $750M, Bloomberg says »

Saracen Mineral Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESPR

Esperion

$40.51

0.67 (1.68%)

15:11
11/17/19
11/17
15:11
11/17/19
15:11
Hot Stocks
Esperion presents pooled analyses from four Phase 3 bempedoic acid studies »

Esperion announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

PCG

PG&E

$7.41

0.71 (10.60%)

15:06
11/17/19
11/17
15:06
11/17/19
15:06
Hot Stocks
PG&E monitoring potential weather event that could lead to power shutoffs »

Pacific Gas and Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

XRX

Xerox

$38.95

0.295 (0.76%)

, HPQ

HP Inc.

$20.17

0.05 (0.25%)

15:04
11/17/19
11/17
15:04
11/17/19
15:04
Hot Stocks
HP unanimously rejects unsolicited Xerox proposal »

HP Inc. (HPQ) announced…

XRX

Xerox

$38.95

0.295 (0.76%)

HPQ

HP Inc.

$20.17

0.05 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 09

    Dec

FOX

Fox Corp.

$33.60

0.14 (0.42%)

, FOXA

Fox Corp.

$34.26

0.04 (0.12%)

14:49
11/17/19
11/17
14:49
11/17/19
14:49
On The Fly
Box Office Battle: 'Ford v Ferrari' races to top, 'Charlie's Angels' disappoints »

"Box Office Battle" is…

FOX

Fox Corp.

$33.60

0.14 (0.42%)

FOXA

Fox Corp.

$34.26

0.04 (0.12%)

LGF.A

Lionsgate

$9.67

0.315 (3.37%)

LGF.B

Lionsgate

$9.07

0.345 (3.96%)

SNE

Sony

$62.03

0.23 (0.37%)

VIA

Viacom

$26.59

1.28 (5.06%)

VIAB

Viacom

$23.07

0.59 (2.62%)

T.CA

TELUS Corp. (Toronto)

$0.00

(0.00%)

CMCSA

Comcast

$44.54

-0.93 (-2.05%)

CMCSK

Comcast

$0.00

(0.00%)

DIS

Disney

$144.63

-2.56 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

13:36
11/17/19
11/17
13:36
11/17/19
13:36
Periodicals
J&J rushed to test baby powder and got complicated results, WSJ says »

In October, Johnson &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 07

    Dec

  • 21

    Jan

BA

Boeing

$371.55

4.25 (1.16%)

13:24
11/17/19
11/17
13:24
11/17/19
13:24
Periodicals
Boeing 737 makes emergency landing after engine malfunction, NY Post says »

A Canada-bound flight…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.46

0.09 (0.19%)

13:17
11/17/19
11/17
13:17
11/17/19
13:17
Hot Stocks
Data shows AstraZeneca's Brilinta reduces risks of clinically relevant bleeding »

New results from a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 07

    Dec

LLY

Eli Lilly

$113.18

1.8 (1.62%)

13:11
11/17/19
11/17
13:11
11/17/19
13:11
Hot Stocks
Analysis shows Jardiance decreased risk of hospitalization for heart failure »

A new interim analysis of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

AZN

AstraZeneca

$47.46

0.09 (0.19%)

13:09
11/17/19
11/17
13:09
11/17/19
13:09
Hot Stocks
AstraZeneca says data shows Farxiga reduces risks in heart failure patients »

AstraZeneca announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 07

    Dec

BA

Boeing

$371.55

4.25 (1.16%)

13:05
11/17/19
11/17
13:05
11/17/19
13:05
Hot Stocks
Boeing, Biman announce order for two 787-9 Dreamliner jets »

Boeing and Biman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBIO

BridgeBio

$28.26

0.55 (1.98%)

, EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

13:03
11/17/19
11/17
13:03
11/17/19
13:03
Hot Stocks
BridgeBio, Eidos present 'positive' data from Phase 2 clinical trial of AG10 »

BridgeBio Pharma (BBIO)…

BBIO

BridgeBio

$28.26

0.55 (1.98%)

EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.